Iovance Biotherapeutics Profit Margin

The latest profit margin for 0JDK.L is -89.09% as of June 2026. That compares with -161.44% in the prior-year period — up 44.8% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Iovance Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, 0JDK.L's profit margin moved from -161.44% to -89.09% — a 44.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Iovance Biotherapeutics's valuation or profitability profile.

Against Healthcare companies, 0JDK.L currently prints -89.09% for profit margin, while the sector average sits near 9.48%. That is roughly 1039.7% below the sector mean. Large gaps often invite a closer look at Iovance Biotherapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Iovance Biotherapeutics converts resources into returns. At -89.09%, 0JDK.L may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -161.44% in the prior-year period — up 44.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 0JDK.L's profit margin (-89.09%), review year-over-year change from -161.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.